We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hemostatic Profile Associated with Migraine with Aura

By LabMedica International staff writers
Posted on 31 May 2021
Nearly 15% of the population in the USA experiences migraine. More...
One subtype of migraine that is not well understood is migraine with aura (MA). Individuals who experience MA often see flashing lights, blind spots, or jagged lines in their visual field prior to onset of their migraine headaches.

Individuals who experience MA also face a heightened risk of stroke and cardiovascular disease, although scientists continue to explore why this correlation exists. Based on prior studies, it is controversial whether enhanced atherosclerosis among individuals with MA is likely to explain the migraine association with stroke, suggesting the existence of alternative mechanisms including endothelial activation or a potential role of hypercoagulability and microemboli.

An international team of Medical Scientists led by Brigham and Women's Hospital (Boston, MA, USA) investigated potential causal relationships between hemostatic profiles and migraine by leveraging largescale genome-wide association study (GWAS) summary statistics for migraine and migraine subtypes (MA and migraine without aura [MO]), and for eight hemostatic factors (including plasma levels or activities of fibrinogen, D-dimer, coagulation factor VII [FVII], coagulation factor VIII [FVIII], coagulation factor XI [FXI], von Willebrand factor [vWF], tissue plasminogen activator [tPA], and plasminogen activator inhibitor-1 [PAI-1] among up to 120,246 individuals), two hemostasis clinical tests (activated partial thromboplastin time [aPTT] and prothrombin time/international normalized ratio [PT/INR], which are commonly used to screen for coagulation-factor deficiencies), as well as serum concentrations of two forms of fibrinopeptide A (fibrinopeptide A [ADSGEGDFXAEGGGVR*] and phosphorylated fibrinopeptide A [ADpSGEGDFXAEGGGVR*]).

The investigators found a strong association between four coagulation factors and migraine susceptibility. They observed that genetically increased levels of three blood clotting factors: coagulation factor VIII, von Willebrand factor, and phosphorylated fibrinopeptide A, and genetically decreased levels of fibrinogen (a protein important in the late stages of the blood clotting process) were all associated, in part, with migraine susceptibility. Interestingly, scientists did not find this association among individuals who experience migraine without aura (MO), indicating a specific relationship between these hemostatic factors and MA.

Yanjun Guo, MD, PhD, of the Division of Preventative Medicine at the Brigham and the first author of the study, said, “It is very exciting that by using Mendelian randomization we were able to show that hemostatic factors are associated with MA. And because in the observational studies we saw that MA patients have a higher risk of stroke, these findings may reveal a potential connection between MA and stroke.”

The authors concluded that their findings suggest potential causal roles of genetically determined elevated FVIII, vWF, phosphorylated fibrinopeptide A, and decreased fibrinogen in migraine susceptibility, especially for MA, but the effects of FVIII and vWF on migraine are not independent from each other. The study was originally published online on April 1, 2021 in the journal Neurology.

Related Links:
Brigham and Women's Hospital



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Biochemical Analyzer
iBC 900
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.